Kaia Health, the US-based developer of an online platform for chronic disease management, has completed a $26m series B round co-led by healthcare services provider Optum.
Optum’s corporate venturing unit, Optum Ventures, co-led the round with Idinvest and Capital300, while Balderton Capital, Symphony Ventures and Heartcore Capital also participated. The company said the round increased its overall funding to $50m.
Founded in 2016, Kaia has created an app-based platform that utilises motion tracking technology to create a digital biomarker that can help measure the health of patients living with chronic diseases without requiring them to travel long distances to a clinic.
The platform covers chronic pain as well as a lung disorder known as chronic obstructive pulmonary disease (COPD) which obstructs breathing. Kaia will now add a third digital therapeutic product to deal with knee and hip osteoarthritis.
The company raised $4m from unnamed investors in a 2016 seed round before adding $10m in a series A led by Balderton Capital in January 2019. Optum Ventures then led an $8m round eight months later.
Optum Ventures partner Heather Roxborough said: “We see tremendous need for digital therapeutic platforms that can treat chronic disease remotely, cost effectively and at scale.
“We are encouraged by Kaia’s initial success addressing chronic pain and their expansion into COPD, as they help people simply and effectively manage chronic conditions using devices already in a patient’s homes, including smartphones and tablets. We look forward to supporting and working closely with Kaia’s team on their next phase of growth.”
